Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 51-75 of 138

  • FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

    This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: - Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. - Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. - Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
    Location: 3 locations

  • Pembrolizumab and Trebananib in Treating Patients with Solid Tumors That Are Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase Ib trial studies side effects and best dose of trebananib when given with pembrolizumab in treating patients with solid tumors that have spread to other places or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trebananib may kill tumor cells by blocking blood vessels that supply the tumor with nutrients and oxygen. Giving pembrolizumab and trebananib may work better in treating patients with solid tumors.
    Location: 3 locations

  • A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

    This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.
    Location: 3 locations

  • Axitinib and Nivolumab in Treating Patients with Advanced Kidney Cancer

    This phase I / II trial studies the side effects and best dose of axitinib when given together with nivolumab and to see how well they work in treating patients with kidney cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib together with nivolumab may work better in treating patients with advanced kidney cancer.
    Location: 3 locations

  • A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)

    The study consists of 2 parts: Dose Escalation phase (Part A) and Expansion phase (Part B). The dose escalation phase will evaluate the safety, tolerability, and PK of avelumab in combination with NHS-IL12 in subjects with locally advanced, unresectable, or metastatic solid tumors. Expansion phase will assess the safety and clinical activity of the combination regimen in selected tumor types. In Expansion phase subjects who have completed the combination treatment of avelumab at a given dose level of NHS-IL12, a safety review will be performed by the Safety monitoring committee in order to make a decision on the next dose level. Successive cohorts of 3 to 6 subjects will be treated with escalating doses of NHS-IL12 with avelumab intravenous (IV).
    Location: 4 locations

  • Lenvatinib / Everolimus or Lenvatinib / Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

    This is a multicenter, randomized, open-label, Phase 3 study to compare the efficacy and safety of lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) versus sunitinib (Arm C) as first-line treatment in participants with advanced renal cell carcinoma.
    Location: 3 locations

  • Stereotactic Body Radiotherapy in Treating Lung Metastases in Patients with Ewing Sarcoma, Rhabdomyosarcoma, or Wilms Tumors

    This phase I / II trial studies the side effects and best dose of stereotactic body radiotherapy and to see how well it works in treating cancer that has spread to the lung in patients with Ewing sarcoma, rhabdomyosarcoma, or Wilms tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
    Location: 3 locations

  • Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab

    This is a phase 1b / 2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. The study consists of 2 parts and 2 groups, and Part 2 includes 2 stages. The objective of Part 1 is to evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors alone and in combination with systemically administered pembrolizumab for the non-HCC (Group A) and HCC (Group B) cohorts separately. Part 2 consists of 2-stage design to evaluate the efficacy and safety of talimogene laherparepvec in combination with systemic pembrolizumab. Efficacy and safety will be evaluated in each of the six non-HCC tumor types from Group A separately. Similarly, the efficacy and safety of the combination treatment will be determined for Group B HCC subjects.
    Location: 5 locations

  • Cabozantinib S-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors

    This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
    Location: 8 locations

  • A Study of XL092 in Subjects With Solid Tumors

    This is a Phase 1, open-label, dose-escalation study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect on biomarkers of XL092 administered orally to subjects with advanced solid tumors.
    Location: 2 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

    The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of NKTR-214 combined with nivolumab to that of a tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC).
    Location: 4 locations

  • A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

    The purpose of this study is to investigate the effects of nivolumab when given under the skin with or without rHuPH20. This study will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: - non-small cell lung cancer (NSCLC) - renal cell carcinoma (RCC) - unresectable or metastatic melanoma - hepatocellular carcinoma (HCC) - microsatellite instability-high or mismatch repair deficient colorectal cancer (MSI-H / dMMR CRC) - in Part B, other solid tumors may be considered at the discretion of the Medical Monitor
    Location: 3 locations

  • Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

    This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
    Location: 2 locations

  • GEN1029 (HexaBody®-DR5 / DR5) Safety Trial in Patients With Malignant Solid Tumors

    The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5 / DR5) in a mixed population of patients with specified solid tumors
    Location: 2 locations

  • A Phase I / Ib Study of NZV930 Alone and in Combination With PDR001 and / or NIR178 in Patients With Advanced Malignancies.

    The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and / or NIR178, in patients with advanced cancers
    Location: 2 locations

  • Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

    This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib / II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have received 0-1 prior therapy but no prior anti-PD-1 / PD-L1 / CTLA4 (Cohort 1, 36 subjects). Study treatment could potentially continue for up to 13 cycles (52 weeks).
    Location: 2 locations

  • A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

    This is a study to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab in participants with advanced solid tumors including the following cohorts: squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), and renal cell carcinoma (RCC).
    Location: 2 locations

  • Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma

    Study E7080-G000-218 is a Randomized, open-label (formerly Double-blind), Phase 2 Trial conducted to assess whether a starting dose of lenvatinib 14 milligrams (mg) in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile compared to lenvatinib 18 mg in combination with everolimus 5 mg (based on treatment-emergent intolerable Grade 2, or any ≥ Grade 3 adverse events (AEs) in the first 24 weeks after randomization).
    Location: 2 locations

  • A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

    The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 3 parts: ABBV-368 dose escalation, ABBV-368 tumor-specific dose expansion (triple negative breast cancer [TNBC] cohort and head and neck cancer cohort) and 18F-AraG Imaging Substudy.
    Location: 2 locations

  • NeoVax, a Personalized Neoantigen Cancer Vaccine, in Combination with Ipilimumab in Treating Patients with Stage III or IV Kidney Cancer

    This trial studies the best dose and side effects of ipilimumab when given together with NeoVax in treating patients with stage III or IV kidney carcinoma. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. NeoVax is made of small protein fragments from a person's kidney cancer cells, called “peptides” and mixed with poly-ICLC (also called Hiltonol), which is an experimental “viral mimic” and an activator of immunity. Poly-ICLC binds proteins on the surface of certain immune cells to make it appear as if a virus is present. When the cells detect the vaccine, they think it is a virus and turn on the immune system. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. This trial is investigating how well neovax and ipilimumab works in treating kidney cancer.
    Location: 2 locations

  • Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

    A Phase 1b / 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC). The primary objective of this study is: -To evaluate the safety and tolerability of HBI-8000 when combined with a standard dose and regimen of nivolumab, to determine Maximum Tolerated Dose (MTD) and / or Recommended Phase 2 Dose (RP2D) and to evaluate frequency and severity of toxicities of this combination treatment The secondary objectives of this study include: - To explore the efficacy of study treatment as measured by Objective Response Rate (ORR), Disease Control Rate (DCR), Clinical Benefit Rate (CBR), Duration of Response (DoR), Progression-Free Survival (PFS) in all subjects treated at RP2D - To obtain pharmacokinetics of twice weekly HBI-8000 when administered in combination with nivolumab administered once every two weeks (Phase 1b all sites; Phase 2 selected sites) - To characterize the effect of HBI-8000 on the electrocardiogram QT corrected (QTc) interval (Phase 1b only) Exploratory: -To investigate the kinetics and extent of histone acetylation in peripheral blood mononuclear cells (PBMC) at the RP2D of HBI-8000 (Phase 2 only) Dose Escalation (Phase 1b) will include up to 18 subjects, followed by Cohort Expansion (Phase 2) including up to 20 subjects per tumor indication at MTD and / or RP2D (including those treated in Phase 1b).
    Location: 2 locations

  • A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

    Background: - Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases - Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non-familial type 1 papillary RCC can present as both solitary renal tumors and as bilateral, multifocal disease - There are no standard agents of proven efficacy for patients with advanced papillary RCC. - Patients with disease localized to the kidney are managed surgically while patients with advanced / unresectable disease are usually managed in the community with VEGF pathway antagonists or mTOR inhibitors. - Activating mutations of MET were identified in the germline of affected HPRC patients, who have a predilection for the development of bilateral, multifocal type 1 papillary RCC. Somatic MET mutations have been found in a subset of patients with non-inherited, sporadic papillary renal carcinoma - The investigational agent INC280 is a selective MET inhibitor lacking activity against the VEGF pathway - This is a proof-of-concept study using INC280 in patients with papillary RCC to test the idea that effectively blocking the HGF / MET pathway will lead to clinical activity in patients with papillary renal cell cancer Objectives: Primary Objective: -To determine the overall response rate (RECIST 1.1) in patients with papillary renal cell carcinoma treated with single agent INC280 Eligibility: - Diagnosis of hereditary papillary renal carcinoma (HPRC) or sporadic papillary renal cell carcinoma (RCC) - Patients with bilateral multifocal disease can have tumors localized to the kidney or have metastatic disease - Patients with sporadic papillary RCC (but without multifocal disease) should have advanced disease that is considered unresectable - ECOG 0-2 - Measurable disease - Adequate organ function - No active brain metastases - Prior therapy - No more than 3 prior lines of systemic therapy - Prior therapy with a MET inhibitor is allowed as long as the patient has not had progressive disease while receiving the agent Design: - This is a phase 2 single center non-randomized trial. - The study will be conducted using a Simon 2 stage minimax design. Initially 13 evaluable subjects will be recruited. If there are no responses to therapy, the study will be terminated. If there is at least 1 response an additional 7 evaluable subjects will be accrued. - The two-stage minimax design is based on assuming an ineffective response rate of 5% and a targeted effective response rate of 25%. We also assume that the probability of accepting an ineffective treatment and the probability of rejecting an effective treatment are each 10%. - Subjects will be dosed orally at a starting dose of 600 mg twice daily. - The overall response rate (complete response + partial response) will be determined.
    Location: 2 locations

  • Vaccine Therapy in Treating Patients with HER2-Positive Solid Tumors

    This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with tumors that have a protein called human epidermal growth factor receptor 2 (HER2) on the surfaces of their cells. Vaccines made from a virus that has been modified to contain HER2 cells may help teach the immune system find and kill tumor cells.
    Location: 2 locations

  • A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

    Background: - At the present time, there are no drugs that have been proven to work in patients with papillary kidney cancer that has spread (metastasized) beyond the kidneys. Researchers are interested in determining whether the combination of the drugs bevacizumab and erlotinib can be used to treat metastatic papillary kidney cancer. - Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is an inherited type of papillary kidney cancer (it runs in families). Papillary kidney cancer can also occur sporadically, or without a family connection. More research is needed to determine whether treatments for papillary kidney cancer, such as bevacizumab and erlotinib, work in inherited or sporadic types of kidney cancer, and if so, whether there are any differences. Objectives: -To determine the effectiveness of the combination of bevacizumab and erlotinib as a treatment for patients with (1) metastatic HLRCC kidney cancer and (2) metastatic kidney cancer not associated with HLRCC (or sporadic papillary RCC). Eligibility: - Individuals 18 years of age or older who have been diagnosed with papillary kidney cancer that has spread beyond the kidneys. - Participants may have either HLRCC or sporadic papillary kidney cancer. Design: - Participants will be screened with a full medical history, physical examination, blood and urine tests, and CT and other scans to evaluate tumor size and treatment options. - Participants will receive 28-day treatment cycles of bevacizumab (given intravenously every 2 weeks) and erlotinib (a tablet taken by mouth daily). - Every cycle, participants will return for regular blood and urine tests. Every other cycle, participants will have imaging scans to assess tumor size and response to treatment. Female participants who have uterine fibroid tumors related to their kidney cancer may have additional scans to assess tumor size and response to treatment. - Participants will continue to receive treatment on the study until their tumors grow or spread to new areas (disease progression), intolerable side effects develop, a better treatment option becomes available, the study closes, it is unsafe to continue treatment, or the participant decides not to remain in the study.
    Location: 2 locations